ArticleJACC. Asia2025
Atrial Fibrillation Screening in the Elderly: A Cost-Effectiveness Analysis for Public Health Policy.
Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Atrial Fibrillation Detected by Handheld ECG and Ischemic Stroke Risk in a 55- to 64-Year-Old Chinese Population.JACC. Asia · 2025Article
- Atrial Fibrillation Screening in Asia: Balancing Costs and Benefits for Optimal Outcomes.JACC. Asia · 2025Article
- Atrial Fibrillation in Asia and Globally: "Easy as ABC," "It's an SOS," or "Handle With CARE".JACC. Asia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) screening identifies undiagnosed patients who can benefit from anticoagulant therapy, thereby reducing the risk of ischemic stroke. However, the long-term outcomes and costs related to population screening for this purpose in the Asian elderly remain unknown. Objectives: This study aimed to evaluate the cost-effectiveness of population screening for AF in the elderly in Taiwan and explore the optimal screening strategy from the health care sector's perspective. Methods: Using a Markov decision-analytic model, we simulated lifetime outcomes and costs of AF screening in a cohort of 10,000 individuals aged 75. Comparative analyses with a nonscreening approach assessed prevented ischemic strokes, quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were conducted to address model uncertainty, while scenario analyses were performed to determine the optimal age and frequency of screening. Results: One-time population screening for AF among 75-year-olds prevented 45 ischemic strokes and gained 47.42 QALYs, with an additional cost of $592,450 (ICER: $12,493 per QALY gained). The cost-effectiveness of screening remained robust in sensitivity analyses, with anticoagulant effectiveness in ischemic stroke prevention being the most influential factor. Similar ICERs were observed for individuals aged 65 to 80 years. Implementing annual screening for individuals aged 65 to 80 years yielded an ICER of approximately $18,000 per QALY gained. Conclusions: Both one-time and annual population screening for AF in individuals aged 65 to 80 years appear to be cost-effective. Further research is needed to assess budgetary and feasibility aspects to establish an optimal screening program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.